Assessing the social value of novel regimens for MDR TB

Location

Baltimore, Maryland, US

Dates

07/01/2014 - 06/01/2015

PI

David Dowdy, MD, PhD, ScM

We are collaborating with investigators from the Berman Bioethics Institute to develop novel techniques for economic evaluation that also incorporate considerations of social value, using novel regimens for MDR-TB as a paradigmatic example.

Projects

ACTG trial A5343

Phase 2 safety study of bedaquiline and delamanid for the treatment of MDR-TB in South Africa

Read More

mHealth for improved TB contact investigation...

This multicenter randomized study is evaluating the implementation, effectiveness, cost-effectiveness, and population-level...

Read More

Evaluating an automated system for...

We are evaluating the accuracy and cost-effectiveness of TBDx, an automated digital microscopy system, as a screening test to...

Read More

A Nurse Case Management Intervention to...

Dr. Farley is responsible for the overall project from design, implementation, data collection, and preparation of...

Read More

Decentralized testing for tuberculosis with...

This is a highly pragmatic cluster randomized trial to compare the impact, implementation, and cost-effectiveness of on-site...

Read More